China Animal Vaccine Industry Report, 2013-2016
  • June 2014
  • Hard Copy
  • USD $2,700
  • Pages:138
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: HK045
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,900
  • Hard Copy + Single User License
  • USD $2,900
      

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main force of traditional animal vaccine markets in the world, still taking around 60% nowadays. In recent years, European and American animal vaccine markets have decelerated growth due to quality safety, high maturity and other factors, while the fast-growing animal vaccine market of China and other emerging countries will become a new highlight.

In 2004-2013, Chinese animal vaccine market size maintained a high growth rate of 26.3%, reaching about RMB11.5 billion in 2013. The growth in 2007-2010 was mainly driven by the expansion of governmental tender vaccine, while that from 2011 was primarily thanks to the market-oriented vaccine expansion. The Chinese animal vaccine market is basically occupied by local companies, showing a self-sufficiency rate of around 90%.

Given the policy factor, Chinese animal vaccine products are divided into compulsory immunization vaccines and market-oriented vaccines. At present, the former include foot-and-mouth disease (FMD), bird flu, porcine reproductive and respiratory syndrome (PRRS), swine fever, and peste des petits ruminants (PPR); the latter refer to porcine circovirus (PCV), Newcastle disease, porcine parvovirus (PPV) and other varieties. Since 2011, the bids for compulsory vaccines proposed by the Chinese government has turned to be more fierce, with limited growth potential; however, market-oriented vaccines have developed faster, enjoying 40%-50% market share in 2013.

According to animal attributes, animal vaccines can be classified into swine vaccines, poultry vaccines, cattle & sheep vaccines, pet vaccines and other vaccines. In 2013, Chinese swine vaccines and poultry vaccines accounted for more than 80% of the animal vaccine market. In addition, the emerging Chinese pet industry is boosting the demand for pet vaccines, but due to lack of commercialized pet vaccines, China now mainly relies on imports. Thus, the Chinese pet vaccine market will see a larger space for development in the future.

As the scale of Chinese farming escalates, the demand for animal vaccines will continue to grow steadily. In the next few years, the Chinese animal vaccine industry is expected to keep a growth rate of approximately 15% and see market value of RMB17.5 billion or so in 2016.

In 2006, China implemented mandatory veterinary drug GMP certification to raise the threshold, resulting in a sharp decline in the number of animal vaccine companies and the accompanying increased industry concentration. In 2013, CAHIC seized the highest market share of 10.5% among Chinese listed animal vaccine companies, followed by Jinyu Group, Tecon and Dahuanong with a combined proportion of 15% or so.

动物疫苗 英文_副本.jpg

China Animal Vaccine Industry Report, 2013-2016 by ResearchInChina covers the followings:
20120114.gifThe market size, market structure and competitive landscape of the global animal vaccine industry;
20120114.gifThe market size, market structure, competitive landscape and import & export of the Chinese animal vaccine industry;
20120114.gifPolicies, social environment and downstream demand of the Chinese animal vaccine industry;
20120114.gifThe size and competitive landscape of Chinese animal vaccine market segments such as swine vaccines and poultry vaccines;
20120114.gifOperation, animal vaccine business, forecast and outlook of 10 Chinese animal vaccine manufacturers;
20120114.gifThe market size and market structure of Chinese animal vaccine market and its segments in 2013-2016E.

1. Overview of Animal Vaccine
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Status Quo of Animal Vaccine Industry
2.1 Global Market
2.1.1 Market Size
2.1.2 Market Structure
2.1.3 Competitive Landscape
2.1.4 New Epidemics and Products
2.2 Chinese Market
2.2.1 Market Size
2.2.2 Market Structure
2.2.3 Import and Export
2.2.4 Profit 
2.2.5 Entry Barriers
2.2.6 Competitive Landscape
2.2.7 Trends

3. Development Environment for China Animal Vaccine Industry 
3.1 Policy Environment
3.1.1 Major Policies
3.1.2 Tendering System for Compulsory Immunization Vaccine 
3.2 Social Environment
3.2.1 Stable Development of Farming Industry
3.2.2 Large-scale Farming Becomes a Trend
3.2.3 Frequent Outbreaks of Animal Epidemics

4. Chinese Animal Vaccine Industry Segments 
4.1 Governmental Mandatory Vaccine  
4.1.1 FMD Vaccine 
4.1.2 Bird Flu Vaccine 
4.1.3 PRRS Vaccine 
4.1.4 Swine Fever Vaccine 
4.2 Market-oriented Vaccine 
4.2.1 PCV Vaccine 
4.2.2 Newcastle Disease Vaccine 
4.3 Pet Vaccine

5. Key Enterprises
5.1 CAHIC 
5.1.1 Profile
5.1.2 Operation 
5.1.3 Revenue Structure 
5.1.4 Gross Margin 
5.1.5 R & D 
5.1.6 Animal Vaccine Business 
5.1.7 Forecast and Outlook
5.2 Jinyu Group 
5.2.1 Profile
5.2.2 Operation 
5.2.3 Revenue Structure 
5.2.4 Gross Margin 
5.2.5 R & D 
5.2.6 Animal Vaccine Business 
5.2.7 Forecast and Outlook
5.3 Tecon
5.3.1 Profile
5.3.2 Operation 
5.3.3 Revenue Structure 
5.3.4 Gross Margin 
5.3.5 R & D 
5.3.6 Clients and Suppliers 
5.3.7 Animal Vaccine Business 
5.3.8 Forecast and Outlook
5.4 Tech-bank
5.4.1 Profile
5.4.2 Operation 
5.4.3 Revenue Structure 
5.4.4 Gross Margin 
5.4.5 R & D 
5.4.6 Animal Vaccine Business 
5.4.7 Forecast and Outlook
5.5 Shenghua Biok 
5.5.1 Profile
5.5.2 Operation 
5.5.3 Revenue Structure 
5.5.4 Gross Margin 
5.5.5 Clients 
5.5.6 Animal Vaccine Business 
5.5.7 Forecast and Outlook
5.6 Ringpu Bio-technology 
5.6.1 Profile
5.6.2 Operation 
5.6.3 Revenue Structure 
5.6.4 Gross Margin 
5.6.5 R & D 
5.6.6 Animal Vaccine Business 
5.6.7 Forecast and Outlook
5.7 Dahuanong 
5.7.1 Profile
5.7.2 Operation 
5.7.3 Revenue Structure 
5.7.4 Gross Margin 
5.7.5 R & D 
5.7.6 Animal Vaccine Business 
5.7.7 Forecast and Outlook
5.8 Hile Bio 
5.8.1 Profile
5.8.2 Operation 
5.8.3 Revenue Structure 
5.8.4 Gross Margin 
5.8.5 R & D 
5.8.6 Clients and Suppliers 
5.8.7 Animal Vaccine Business 
5.8.8 Forecast and Outlook
5.9 Yikang 
5.9.1 Profile
5.9.2 Operation 
5.9.3 Revenue Structure 
5.9.4 Gross Margin 
5.9.5 R & D 
5.9.6 Clients and Suppliers 
5.9.7 Animal Vaccine Business 
5.10 Chopper 
5.10.1 Profile
5.10.2 Operation 
5.10.3 Revenue Structure 
5.10.4 Gross Margin 
5.10.5 R & D 
5.10.6 Clients and Suppliers 
5.10.7 Animal Vaccine Business 

6. Summary and Forecast
6.1 Summary
6.2 Development Forecast
6.2.1 Swine Vaccine
6.2.2 Poultry Vaccine
6.2.3 Cattle and Sheep Vaccine
6.2.4 Pet Vaccine
Classification of Animal Health Products
Animal Vaccine Types (by Constituent and Feature) and Characteristics
Animal Vaccine Industry Chain
Classification of Animal Epidemics in China
Global Animal Vaccine Market Size, 2008-2016E
Profile of Global Animal Health Products Giants
Commercialized Vaccines and Manufacturers in Overseas Market in Recent Years
Development Process of Chinese Compulsory Vaccination Policies
Chinese Animal Vaccine Market Size, 2004-2013
China’s Animal Vaccine Net Import Value and Dependence on Export, 2008-2013
China’s Animal Vaccine Product Structure (by Animal Species), 2010-2013
China’s Animal Vaccine Product Structure (by Vaccine Type), 2010-2013
China’s Animal Vaccine Import and Export Volume, 2009-2014
China’s Average Animal Vaccine Import and Export Prices, 2009-2014
China’s Animal Vaccine Import Sources (by Import Volume), 2013
China’s Animal Vaccine Export Destinations (by Export Volume), 2013
Main Regions Which Import Animal Vaccines and Their Share in Import Volume in China, 2013
Main Regions Which Export Animal Vaccines and Their Share in Export Volume in China, 2013
Gross Margin of Animal Vaccine Business of Major Listed Animal Vaccine Companies in China, 2011-2013 
Barriers to Entry into Animal Vaccine Industry in China
Major Chinese Animal Vaccine Manufacturers and Their Capacity, 2013
Competitive Landscape of China Animal Vaccine Industry, 2013
Gap between Chinese Vaccine Production Process and International Advanced Level
Sino-foreign Joint Animal Vaccine Enterprises, 1990-2013
Major Polices on China Animal Vaccine Industry, 2010-2014
Compulsory Immunization Plan of Animal Epidemics in China, 2013
Animal Diseases worth Priority Prevention in China, 2013-2020
Defects of Compulsory Vaccination Tender System in China
Direction for Compulsory Vaccination Tender System Reform in China
Output of Meat, Eggs and Milk in China, 2009-2013
China’s Meat Product Structure (by Output), 2011-2013
Farming Scale Degree in China, 2010-2020E
Overview of Common Animal Epidemics in China
Animal Epidemic Summary in China, 2013
China’s Animal Vaccine Market Structure (by Sales Method)
Competitive Landscape of Main Compulsory Immunization Vaccine Markets in China, 2013
Performance Comparison between Swine Fever Vaccines in China
Classification and Market Conditions of Market-oriented Vaccines in China
Market Capacity of Some Compulsory Market-oriented Vaccines in China, 2013
Market Capacity of Some Non-compulsory Vaccines in China, 2013
Market Capacity of Newcastle Disease Vaccine and Market Share of Ringpu Bio-technology
Pet Vaccine Suppliers in Chinese Market and Their Products
CAHIC’s Revenue and Net Income, 2009-2013
CAHIC’s Revenue (by Product), 2011-2013
CAHIC’s Revenue Structure (by Product), 2011-2013 
CAHIC’s Revenue (by Region), 2011-2013
CAHIC’s Revenue Structure (by Region), 2011-2013 
Gross Margin of CAHIC’s Main Products, 2011-2013  
CAHIC’s R & D Costs and % of Total Revenue, 2011-2013
CAHIC's Animal Vaccine Subsidiaries and Their Products 
CAHIC's Animal Vaccine Projects under Construction, 2014
CAHIC's Revenue and Net Income, 2012-2016E
Jinyu Group’s Revenue and Net Income, 2009-2013 
Jinyu Group’s Revenue (by Product), 2011-2013
Jinyu Group’s Revenue Structure (by Product), 2011-2013 
Jinyu Group’s Revenue (by Region), 2011-2013 
Jinyu Group’s Revenue Structure (by Region), 2011-2013 
Gross Margin of Jinyu Group’s Main Business, 2010-2013
Jinyu Group’s R & D Costs and % of Total Revenue, 2011-2013 
Animal Vaccine Subsidiaries of Jinyu Group, 2013
Revenue and Net Income of Spirit Jinyu, 2012-2013
Jinyu Group’s Revenue and Net Income, 2012-2016E
Tecon’s Revenue and Net Income, 2009-2013 
Tecon’s Revenue (by Product), 2011-2013
Tecon’s Revenue Structure (by Product), 2011-2013 
Tecon’s Revenue (by Region), 2011-2013 
Tecon’s Revenue Structure (by Region), 2011-2013 
Gross Margin of Tecon’s Main Products, 2011-2013  
Tecon’s R & D Costs and % of Total Revenue, 2011-2013
Tecon’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013
Name List and Revenue Contribution of Tecon’s Top 5 Clients, 2013
Tecon’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2013
Name List and Procurement Contribution of Tecon’s Top 5 Suppliers, 2013
Tecon’s Animal Vaccine Production Bases and Capacity, 2013
Tecon’s Revenue and Net Income, 2012-2016E
Tech-bank’s Revenue and Net Income, 2009-2013 
Tech-bank’s Revenue (by Product), 2011-2013
Tech-bank’s Revenue Structure (by Product), 2011-2013 
Tech-bank’s Revenue (by Region), 2011-2013 
Tech-bank’s Revenue Structure (by Region), 2011-2013 
Tech-bank’s Gross Margin of Main Products, 2011-2013  
Tech-bank’s R & D Costs and % of Total Revenue, 2011-2013
Revenue and Net Income of Chengdu TECBOND, 2010-2013
Tech-bank’s Revenue and Net Income, 2012-2016E
Shenghua Biok’s Revenue and Net Income, 2009-2013 
Shenghua Biok’s Revenue (by Product), 2011-2013
Shenghua Biok’s Revenue Structure (by Product), 2011-2013 
Shenghua Biok’s Revenue (by Region), 2011-2013 
Shenghua Biok’s Revenue Structure (by Region), 2011-2013 
Gross Margin of Shenghua Biok’s Main Products, 2011-2013
Shenghua Biok’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013 
Name List and Revenue Contribution of Shenghua Biok’s Top 5 Clients, 2013  
Revenue and Net Income of Qingdao Yebio, 2009-2013
Shenghua Biok’s Revenue and Net Income, 2012-2016E
Ringpu Bio-technology’s Revenue and Net Income, 2009-2013 
Ringpu Bio-technology’s Revenue (by Product), 2011-2013
Ringpu Bio-technology’s Revenue Structure (by Product), 2011-2013 
Ringpu Bio-technology’s Revenue (by Region), 2012-2013 
Ringpu Bio-technology’s Revenue Structure (by Region), 2012-2013 
Ringpu Bio-technology’s Gross Margin of Main Products, 2011-2013  
Ringpu Bio-technology’s R & D Costs and % of Total Revenue, 2011-2013 
Ringpu Bio-technology’s Animal Vaccine Output and Sales Volume (by Product), 2011-2013
Sales and Gross Margin of Ringpu Bio-technology’s Animal Vaccines (by Product), 2013
Ringpu Bio-technology’s Animal Vaccine Subsidiaries and Their Products, 2013
Revenue and Net Income of Ringpu Bio-technology’s Animal Vaccine Subsidiaries, 2013 
Ringpu Bio-technology’s Animal Vaccine Projects under Construction, 2013
Ringpu Bio-technology’s Revenue and Net Income, 2012-2016E  
Dahuanong’s Revenue and Net Income, 2009-2013 
Dahuanong’s Revenue Structure (by Product), 2011-2013
Dahuanong’s Revenue Structure (by Product), 2011-2013
Dahuanong’s Revenue (by Region), 2011-2013
Dahuanong’s Revenue Structure (by Region), 2011-2013
Gross Margin of Dahuanong’s Main Products, 2011-2013
Dahuanong’s R & D Costs and % of Total Revenue, 2011-2013
Capacity of Dahuanong’s Animal Vaccine Products, 2010-2013  
Output, Sales Volume and Sales-output Ratio of Dahuanong’s Veterinary Biologics, 2012-2013
Dahuanong’s Revenue and Net Income, 2012-2016E  
Hile Bio’s Main Products
Hile Bio’s Revenue and Net Income, 2011-2013
Hile Bio’s Revenue Structure (by Product), 2011-2013
Hile Bio’s Revenue Structure (by Product), 2011-2013
Hile Bio’s Revenue (by Region), 2011-2013 
Hile Bio’s Revenue Structure (by Region), 2011-2013
Gross Margin of Hile Bio’s Main Products, 2011-2013
Hile Bio’s R & D Costs and % of Total Revenue, 2011-2013
Name List and Revenue Contribution of Hile Bio’s Top 5 Clients, 2013
Hile Bio’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2013 
Name List and Procurement Contribution of Hile Bio’s Suppliers, 2013
Hile Bio’s Revenue Structure (by Product), 2013
Hile Bio’s Revenue Structure (by Sales Method), 2011-2013
Hile Bio’s Swine Vaccine Capacity, Output and Sales Volume, 2011-2013
Selling Prices of Hile Bio’s Main Products, 2011-2013   
Hile Bio’s Animal Vaccine Fundraising Projects, 2014 
Hile Bio’s Revenue and Net Income, 2012-2016E  
Yikang’s Revenue and Net Income, 2009-2011 
Yikang’s Revenue Structure (by Product), 2009-2011
Yikang’s Revenue Structure (by Product), 2009-2011
Yikang’s Revenue (by Region), 2009-2011 
Yikang’s Revenue Structure (by Region), 2009-2011
Gross Margin of Yikang’s Main Products, 2009-2011
Yikang’s R & D Costs and % of Total Revenue, 2009-2011 
Yikang’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2011
Name List and Revenue Contribution of Yikang’s Top 5 Clients, 2011
Yikang’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2011
Name List and Procurement Contribution of Yikang’s Suppliers, 2011
Yikang’s Animal Vaccine Production Lines, 2009-2011
Yikang’s Capacity, Output and Capacity Utilization, 2009-2011 
Yikang’s Output, Sales Volume and Sales-output Ratio, 2009-2011 
Average Selling Price of Yikang’s Main Products, 2009-2011
Yikang’s Revenue Structure (by Sales Method), 2009-2011
Chopper’s Revenue and Net Income, 2009-2011 
Chopper’s Revenue (by Product), 2011-2013
Chopper’s Revenue Structure (by Product), 2011-2013
Chopper’s Revenue (by Region), 2011-2013 
Chopper’s Revenue Structure (by Region), 2011-2013
Sales of Chopper's Main Vaccine Products, 2011-2013
Chopper’s R & D Costs and % of Total Revenue, 2011-2013
Chopper’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2013
Name List and Revenue Contribution of Chopper’s Top 5 Clients, 2013
Chopper’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2013
Name List and Procurement Contribution of Chopper’s Suppliers, 2013
Chopper’s Products and Clients (by Sales Method)
Chopper’s Sales Structure by Sales Method, 2011-2013
Sales of Chopper’s Main Vaccine Products, 2011-2013
Chopper’s Sales Structure by Main Vaccine Product, 2011-2013
Chopper’s Vaccine Capacity, Output and Capacity Utilization, 2011-2013
Chopper’s Vaccine Output, Sales Volume and Sales-output Ratio, 2011-2013
Average Selling Price of Chopper’s Main Vaccine Products, 2011-2013
Chopper’s Investment Plan, 2014
Animal Vaccine Revenue of Major Animal Vaccine Companies in China, 2011-2013 
Chinese Animal Vaccine Market Size, 2012-2016E
Chinese Animal Vaccine Market Structure (by Animal Attributes), 2013 vs 2016E 
Chinese Swine Vaccine Market Size, 2012-2016E
Chinese Poultry Vaccine Market Size, 2012-2016E

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号